Page 1656 - Clinical Small Animal Internal Medicine

1594 Index

chronic enteropathies (CE) (cont’d) motility disorders 572 CKD see chronic kidney disease
VetBooks.ir genetics and genetic testing polyunsaturated fatty endoscopy 511–512, 511–512
cleaning and disinfection
phosphorus homeostasis and
627–628, 634–635
disorders 1083–1085
kennels and multicat
histology and WSAVA scoring 635
history and clinical signs acids 1169, 1172 environments 1064–1065
629–630, 629 prognosis 1173 nocosomial and multidrug‐resistant
immunohistochemistry proteinuria 1165, 1166, infections 1061
for P‐glycoprotein 634 1168–1170, 1169 client communication
intestinal microbiota 628–629 systemic hypertension 220–221, approach to the dermatologic
intestinal mucosal immune 1165, 1167, 1168–1170 patient 1396
system 628 chronic lymphocytic leukemia behavioral problems 1577–1578
perinuclear antineutrophilic (CLL) 1223–1225, 1224 critical care setting 348
cytoplasmic antibodies 634 chronic myelogenous leukemia clindamycin 783–784
polymerase chain reaction for (CML) 1227–1228 Clinical and Laboratory Standards
antigen receptor chronic, recurrent pyoderma Institute (CLSI) 1192–1193
rearrangement 633 1464–1465 clinical decision making 17–25
prognosis 637 CHV see canine hepacivirus; canine case–control studies 18, 21–23
serum albumin herpesvirus clinical trials 23–25
concentration 630–632 chylothorax 338, 341–343, 342 cohort studies 19–21, 20
serum and fecal markers of CILBD see canine idiopathic large cross‐over trials 24–25
disease 630–635 bowel diarrhea hospital‐based cross‐sectional
serum cobalamin CIRCI see critical illness‐related studies 17–18
concentration 632 corticosteroid deficiency longitudinal observational studies
severe protein‐losing circulating biomarkers see blood 18–25
enteropathy 636–637 chemistry/serology randomized masked clinical
steroid‐responsive diarrhea 627, CIRD see canine infectious respiratory trials 23–24
629, 634 disease clinical trials
supplementation recommendations cirrhosis 705–711 clinical decision making 23–25
for cobalamin 632 acquired portosystemic cross‐over trials 24–25
treatment 635–637 shunts 706–708 randomized masked clinical
work‐up and diagnostic tests 635 ascites 705–706, 709–710 trials 23–24
chronic gastric outlet 485, 485–486 coagulation disturbances clipping 615
chronic kidney disease 706–707, 711 CLL see chronic lymphocytic leukemia
(CKD) 1165–1173 cytology and fluid analysis 708 Clostridium spp. 768–769,
alkalinization therapy 1172 diagnosis 707–709 807–808
anemia 1170–1171 diagnostic imaging 666 see also botulism; tetanus
antinausea and appetite stimulant etiology/pathophysiology clot‐labeling techniques 319
therapy 1167–1168 705–706, 706 clotting times 689
antioxidant therapy 1172 gastrointestinal ulceration 706, CLSI see Clinical and Laboratory
calcitriol 1172 710–711 Standards Institute
dialysis 1178–1179 hepatic encephalopathy 706, 710 CML see chronic myelogenous
diet and nutrition 1166 hepatobiliary disease 673 leukemia
disease staging 1165, 1166, 1167 hepatoprotectants 711 CMM see canine malignant melanoma
enteric dialysis and the histopathology 708–709 CMO see craniomandibular osteopathy
microbiome 1172 history and clinical signs 707 CO see cardiac output
feline hyperthyroidism 79 imaging 708 coagulation and coagulopathies
fluid therapy 1170 laboratory testing 707–708 acute poisoning 438, 439
gastritis and gastric ulceration 551 metabolic diseases 681–683 canine inflammatory liver
hypokalemia 1171 monitoring 711 disease 698
leptospirosis 946, 948 portal hypertension 705, 711 cirrhosis 706–707, 711
medical management 1166–1172 prognosis 711 critical care setting 350
metabolic bone diseases 1522 signalment 707 heat stroke 436
mineral and bone disorder: treatment 709–711 liver disease 644, 650, 656
hyperphosphatemia 1171, 1171 cisterna chyli ablation 343 mast cell tumors 1362
monitoring CKD CIV see canine influenza virus pathophysiology 644
patients 1172–1173 CK see creatine kinase septic shock 423, 426